{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:30:53Z","timestamp":1757622653008,"version":"3.44.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-14816-0","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T01:52:26Z","timestamp":1754531546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of data on biosimilar prescription rates in rheumatology practice from a reference center in Turkey"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-0907","authenticated-orcid":false,"given":"H\u00fcseyin","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8143-3048","authenticated-orcid":false,"given":"Gizem","family":"Cengiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-1104","authenticated-orcid":false,"given":"Hasan","family":"Kara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1290-9540","authenticated-orcid":false,"given":"\u0130sa","family":"C\u00fcce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-2351","authenticated-orcid":false,"given":"Mehmet","family":"Kirnap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1184-0772","authenticated-orcid":false,"given":"Mustafa","family":"\u00c7ali\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"14816_CR1","doi-asserted-by":"publisher","first-page":"e0123582","DOI":"10.1371\/journal.pone.0123582","volume":"10","author":"B Michelsen","year":"2015","unstructured":"Michelsen, B. et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PloS One. 10, e0123582 (2015).","journal-title":"PloS One"},{"key":"14816_CR2","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s10067-018-4105-3","volume":"37","author":"K Tymms","year":"2018","unstructured":"Tymms, K. et al. Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. Clin. Rheumatol. 37, 1617\u20131623 (2018).","journal-title":"Clin. Rheumatol."},{"key":"14816_CR3","doi-asserted-by":"publisher","first-page":"e069681","DOI":"10.1136\/bmjopen-2022-069681","volume":"13","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Factors influencing choice of b\/ts DMARDs in managing inflammatory arthritis from a patient perspective: a systematic review of global evidence and a patient-based survey from Hong Kong. BMJ Open. 13, e069681 (2023).","journal-title":"BMJ Open."},{"key":"14816_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00296-016-3444-0","volume":"36","author":"E Mysler","year":"2016","unstructured":"Mysler, E. et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol. Int. 36, 613\u2013625 (2016).","journal-title":"Rheumatol. Int."},{"key":"14816_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","volume":"79","author":"A Sepriano","year":"2020","unstructured":"Sepriano, A. et al. Safety of synthetic and biological dmards: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 79, 760\u2013770 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"14816_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/rheumatology\/key338","volume":"58","author":"IC Olsen","year":"2019","unstructured":"Olsen, I. C. et al. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. Rheumatology 58, 481\u2013491 (2019).","journal-title":"Rheumatology"},{"key":"14816_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s10067-020-05001-x","volume":"39","author":"AA Drosos","year":"2020","unstructured":"Drosos, A. A., Pelechas, E. & Voulgari, P. V. Treatment strategies are more important than drugs in the management of rheumatoid arthritis. Clin. Rheumatol. 39, 1363\u20131368 (2020).","journal-title":"Clin. Rheumatol."},{"key":"14816_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro, S. et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann. Rheum. Dis. 82, 19\u201334 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"14816_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"14816_CR10","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/rheumatology\/kex277","volume":"56","author":"H Schulze-Koops","year":"2017","unstructured":"Schulze-Koops, H. & Skapenko, A. Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm. Rheumatology 56, iv30\u2013iv48 (2017).","journal-title":"Rheumatology"},{"key":"14816_CR11","first-page":"829","volume":"37","author":"Q Wu","year":"2023","unstructured":"Wu, Q., Wang, Z., Wang, X., Yu, H. & Sun, J. Patients\u2019 Perceptions Biosimilars: Syst. Rev. BioDrugs 37, 829\u2013841 (2023).","journal-title":"Patients\u2019 Perceptions Biosimilars: Syst. Rev. BioDrugs"},{"key":"14816_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/14712598.2020.1812575","volume":"21","author":"JW Kim","year":"2021","unstructured":"Kim, J. W., Jung, J. Y. & Suh, C. H. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. Expert Opin. Biol. Ther. 21, 57\u201373 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"14816_CR13","doi-asserted-by":"publisher","first-page":"104467","DOI":"10.1016\/j.phrs.2019.104467","volume":"149","author":"FC Araujo","year":"2019","unstructured":"Araujo, F. C., Goncalves, J. & Fonseca, J. E. Biosimilars in rheumatology. Pharmacol. Res. 149, 104467 (2019).","journal-title":"Pharmacol. Res."},{"key":"14816_CR14","doi-asserted-by":"crossref","unstructured":"Malik, M. & Holroyd, C. An Update on Biosimilars in Rheumatic and Musculoskeletal Disorders. (2023).","DOI":"10.17925\/RMD.2023.2.1.46"},{"key":"14816_CR15","first-page":"86","volume":"9","author":"AB Iskit","year":"2022","unstructured":"Iskit, A. B. Key concepts in biosimilar medicines: what physicians must know. Northern Clin. Istanbul 9, 86-91 (2022).","journal-title":"Northern Clin. Istanbul"},{"key":"14816_CR16","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper, J. et al. The assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann. Rheum. Dis. 68, ii1\u2013ii44 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"14816_CR17","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American college of rheumatology\/european league against rheumatism collaborative initiative. Arthr. Rhuem. 62, 2569\u20132581 (2010).","journal-title":"Arthr. Rhuem."},{"key":"14816_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-018-0740-6","volume":"20","author":"NA Jassim","year":"2018","unstructured":"Jassim, N. A. & Humadi, Y. A. The use of biosimilars in the middle East. Curr. Rheumatol. Rep. 20, 1\u20137 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"14816_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/CEOR.S231558","volume":"12","author":"CJ Van De Laar","year":"2020","unstructured":"Van De Laar, C. J. et al. Cost-effectiveness of a JAK1\/JAK2 inhibitor vs a biologic disease-modifying antirheumatic drug (bDMARD) in a treat-to-target strategy for rheumatoid arthritis. ClinicoEconomics Outcomes Research, 12, 213\u2013222 (2020).","journal-title":"ClinicoEconomics Outcomes Research"},{"key":"14816_CR20","unstructured":"Goll, G. L. & Kvien, T. K. in Mayo Clinic Proceedings. 4\u20136 (Elsevier)."},{"key":"14816_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/17425255.2023.2270407","volume":"19","author":"YJ Song","year":"2023","unstructured":"Song, Y. J., Nam, S. W., Suh, C. H., Choe, J. Y. & Yoo, D. H. Biosimilars in the treatment of rheumatoid arthritis: a Pharmacokinetic overview. Expert Opin. Drug Metab. Toxicol. 19, 751\u2013768 (2023).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"14816_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40259-023-00636-z","volume":"38","author":"H Woo","year":"2024","unstructured":"Woo, H., Shin, G., Lee, D., Kwon, H. Y. & Bae, S. Is the availability of biosimilar adalimumab associated with budget savings?? A Difference-in-Difference analysis of 14 countries. BioDrugs 38, 133\u2013144 (2024).","journal-title":"BioDrugs"},{"key":"14816_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s41927-022-00309-4","volume":"6","author":"T Khoo","year":"2022","unstructured":"Khoo, T. et al. Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions. BMC Rheumatol. 6, 79 (2022).","journal-title":"BMC Rheumatol."},{"key":"14816_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5152\/eurjrheum.2020.20080","volume":"8","author":"A Becciolini","year":"2020","unstructured":"Becciolini, A. et al. bDMARDs retention rate in the biosimilar era: A real-life monocentric study. Eur. J. Rheumatol. 8, 109 (2020).","journal-title":"Eur. J. Rheumatol."},{"key":"14816_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3899\/jrheum.2024-0001","volume":"51","author":"MP Mart\u00ednez-Vidal","year":"2024","unstructured":"Mart\u00ednez-Vidal, M. P. et al. Long-Term survival of subcutaneous biosimilar tumor necrosis factor inhibitors compared to originators: results from a multicenter prospective registry. J. Rhuematol. 51, 877\u2013883 (2024).","journal-title":"J. Rhuematol."},{"key":"14816_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00296-022-05237-7","volume":"43","author":"NE Ouardi","year":"2023","unstructured":"Ouardi, N. E. et al. Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort study. Rheumatol. Int. 43, 79\u201387 (2023).","journal-title":"Rheumatol. Int."},{"key":"14816_CR27","doi-asserted-by":"crossref","unstructured":"Mohd Sani, N., Aziz, Z. & Kamarulzaman, A. Use of Biosimilars: A Systematic Review of Published Position Statements and Recommendations from Health Organisations and Societies. BioDrugs, 1\u201319 (2024).","DOI":"10.1007\/s40259-024-00649-2"},{"key":"14816_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40259-022-00546-6","volume":"36","author":"HP Cohen","year":"2022","unstructured":"Cohen, H. P. et al. Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. BioDrugs 36, 625\u2013637 (2022).","journal-title":"BioDrugs"},{"key":"14816_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/jpm12030335","volume":"12","author":"A Becciolini","year":"2022","unstructured":"Becciolini, A. et al. Adalimumab and ABP 501 in the treatment of a large cohort of patients with inflammatory arthritis: a real life retrospective analysis. J. Personalized Med. 12, 335 (2022).","journal-title":"J. Personalized Med."},{"key":"14816_CR30","doi-asserted-by":"publisher","first-page":"16178","DOI":"10.1038\/s41598-020-73183-0","volume":"10","author":"MC Ditto","year":"2020","unstructured":"Ditto, M. C. et al. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. Sci. Rep. 10, 16178 (2020).","journal-title":"Sci. Rep."},{"key":"14816_CR31","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/jcm11030621","volume":"11","author":"S Parisi","year":"2022","unstructured":"Parisi, S. et al. Efficacy and drug survival after switching from etanercept to the biosimilar SB4: a real-life long-term study. J. Clin. Med. 11, 621 (2022).","journal-title":"J. Clin. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14816-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:14:16Z","timestamp":1757369656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14816-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14816"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14816-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Local ethics committee approval was received (Date:31 January 2024, Approval Number:2024\/59) and the tenets of Declaration of Helsinki was followed for the study. Due to the retrospective nature of our study, ethics committee waived informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"28853"}}